{
    "root": "e7414f2d-d7cf-41e5-b457-f5850e8bb7a7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rizatriptan Benzoate",
    "value": "20250201",
    "ingredients": [
        {
            "name": "RIZATRIPTAN BENZOATE",
            "code": "WR978S7QHH"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        }
    ],
    "indications": "rizatriptan benzoate tablets indicated acute treatment migraine without aura adults pediatric patients 6 17 years old . limitations • rizatriptan benzoate tablets used clear diagnosis migraine established . patient response first migraine attack treated rizatriptan benzoate tablets , diagnosis migraine reconsidered rizatriptan benzoate tablets administered treat subsequent attacks . •rizatriptan benzoate tablets indicated management hemiplegic basilar migraine [ ( 4 ) ] . •rizatriptan benzoate tablets indicated prevention migraine attacks . •safety effectiveness rizatriptan benzoate tablets established cluster headache .",
    "contraindications": "• adults : 5 mg 10 mg single dose ; separate repeat doses least two hours ; maximum dose 24-hour period : 30 mg ( 2.1 ) • pediatric patients 6 17 years : 5 mg single dose patients less 40 kg ( 88 lb ) ; 10 mg single dose patients 40 kg ( 88 lb ) ( 2.2 ) • adjust dose co-administered propranolol ( 2.4 )",
    "warningsAndPrecautions": "rizatriptan benzoate tablets usp , 10 mg pale pink-colored , circular , flat , beveled-edge uncoated tablets debossed ‘ x ’ one side ‘ 14 ’ side . tablets may mottled . 12 ( 4 x 3 ) unit-dose tablets ndc 82804-202-12 storage store rizatriptan benzoate tablets usp 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "rizatriptan benzoate tablets contraindicated patients : • ischemic coronary artery disease ( angina pectoris , history myocardial infarction , documented silent ischemia ) , significant underlying cardiovascular disease [ ( 5.1 ) ] . •coronary artery vasospasm including prinzmetal 's angina [ ( 5.1 ) ] . •history stroke transient ischemic attack ( tia ) [ ( 5.4 ) ] . •peripheral vascular disease ( pvd ) [ ( 5.5 ) ] . •ischemic bowel disease [ ( 5.5 ) ] . •uncontrolled hypertension [ ( 5.8 ) ] . •recent ( i.e . , within 24 hours ) another 5-ht1 agonist , ergotamine-containing medication , ergot-type medication ( dihydroergotamine methysergide ) [ ( 7.2 7.3 ) ] . •hemiplegic basilar migraine [ usage ( 1 ) ] . •concurrent recent discontinuation ( i.e . , within 2 weeks ) mao-a inhibitor [ ( 7.5 ) pharmacology ( 12.3 ) ] . •hypersensitivity rizatriptan excipients ( angioedema anaphylaxis seen ) [ ( 6.2 ) ] .",
    "indications_original": "Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.\n                  \n                     Limitations of Use\n                  \n                  \n                     \n                        •\n                        Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks.\n                     \n                     \n                        •Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. \n                     \n                        •Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. \n                     \n                        •Safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache.",
    "contraindications_original": "• Adults: 5 mg or 10 mg single dose; separate repeat doses by at least two hours; maximum dose in a 24-hour period: 30 mg (2.1) • Pediatric patients 6 to 17 years: 5 mg single dose in patients less than 40 kg (88 lb); 10 mg single dose in patients 40 kg (88 lb) or more ( 2.2 ) • Adjust dose if co-administered with propranolol (2.4)",
    "warningsAndPrecautions_original": "Rizatriptan Benzoate Tablets USP, 10 mg are a pale pink-colored, circular, flat, beveled-edge uncoated tablets debossed with ‘X’ on one side and ‘14’ on other side. The tablets may be mottled.\n                                  12 (4 x 3) Unit-dose Tablets                     NDC 82804-202-12\n                     \n                     \n                     \n                        Storage\n                     \n                     \n                     \n                      Store rizatriptan benzoate tablets USP at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Rizatriptan benzoate tablets are contraindicated in patients with:\n                  \n                     \n                        •\n                        Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions (5.1)].\n                     \n                     \n                        •Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions (5.1)].\n                     \n                        •History of stroke or transient ischemic attack (TIA) [see \n                           Warnings and Precautions (5.4)].\n                     \n                        •Peripheral vascular disease (PVD) [see Warnings and Precautions (5.5)].\n                     \n                        •Ischemic bowel disease [see Warnings and Precautions (5.5)].\n                     \n                        •Uncontrolled hypertension [see Warnings and Precautions (5.8)].\n                     \n                        •Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3)]. \n                     \n                        •Hemiplegic or basilar migraine [see Indications and Usage (1)].\n                     \n                     \n                        •Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].\n                     \n                        •Hypersensitivity to rizatriptan or any of the excipients (angioedema and anaphylaxis seen) [see Adverse Reactions (6.2)]."
}